DPP4 and autoimmune disease: In large, prospective, population‐based cohort studies, the risk of developing an autoimmune disease was lower in patients receiving antidiabetic therapy with DPP-4 inhibitors compared to T2D patients not treated with DPP-4 inhibitors (133, 134).